Stockscreener 앱 받기
10.20
3.23%
-0.34
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
(OCUL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long‑Term Investor Base? - simplywall.st
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
FDA approves Dextenza for third indication: Ocular itching from allergic conjunctivitis - Ophthalmology Times Europe
Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey? - Sahm
Ocular Therapeutix (OCUL) Holds Steady Near Key Support Levels Amid Low VolumeOn Balance Volume - dars.gov.et
Ocular Therapeutix options trading jumps to 9,894 contracts By Investing.com - Investing.com Canada
Ocular Therapeutix options trading jumps to 9,894 contracts - Investing.com
Ocular Therapeutix Inc (OCUL) Institutional Confidence - TradingKey
Ocular Therapeutix Inc Actuals & Estimates (NASDAQ:OCUL) - TradingView
Price to earnings forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Ocular Therapeutix Inc to Host Investor Day Transcript - GuruFocus
Enterprise value to revenue forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Price to sales forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Price to book forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Enterprise value to EBIT forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Enterprise value to EBITDA forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView
Ocular Therapeutix to present new retinal disea... - Pluang
Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)? - simplywall.st
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences - GlobeNewswire
(OCUL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2000 Value Benchmark - marketscreener.com
Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback - Sahm
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2500 Value Benchmark - marketscreener.com
Ocular Therapeutix, Inc.(NasdaqGM:OCUL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
OCUL Forecast — Price Target — Prediction for 2027 - TradingView
Ocular Therapeutix Inc Actuals & Estimates (BX:0OT) - TradingView
Ocular Therapeutix Inc Actuals & Estimates (HAM:0OT) - TradingView
Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $23 - Moomoo
OCUL Maintained by Chardan Capital -- Price Target Raised to $23 - GuruFocus
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli? - Yahoo Finance
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $27 - Moomoo
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
OCUL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL) - The Globe and Mail
Ocular Therapeutix Inc (OCUL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OCUL Maintained by Baird -- Price Target Raised to $30.00 - GuruFocus
Pravin Dugel (OCUL) reports bona fide gifts of 100,184 OCULAR THERAPEUTIX shares - Stock Titan
Ocular to submit Axpaxli NDA for wet AMD in Q4 - MSN
OCUL Reiterates by HC Wainwright & Co. -- Price Target Raised to $25.00 - GuruFocus
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos - Yahoo Finance
Ocular Therapeutix Inc (OCUL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocular Therapeutix Inc (OCUL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor DaySlideshow (NASDAQ:OCUL) 2026-06-17 - Seeking Alpha
Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcript : Ocular Therapeutix, Inc.Analyst/Investor Day - marketscreener.com
Ocular Therapeutix (OCUL) Plans NDA Submission for AXPAXLI and T - GuruFocus
Why Ocular Therapeutix (OCUL) Stock Is Up Today - Yahoo Finance
Ocular Therapeutix (OCUL) Advances NDA for Axpaxli with FDA Agre - GuruFocus
Ocular Therapeutix (OCUL) Plans Investor Day to Discuss NDA Subm - GuruFocus
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program - Benzinga
Ocular Therapeutix stock dips on NDA submission timeline By Investing.com - Investing.com Australia
2.64%
자본화:
|
볼륨(24시간):